Invesaro

Stocks Health care KRYS

NASDAQ · Health care

Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. brought in $440.5M of revenue over the twelve months to June 30, 2026, up 22.6% from a year earlier. Net income was $241.5M, a net margin of 54.8%. Operating cash flow minus capital spending left $188.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $427.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.

Price
$345.82
+0.25% on the day · September 25, 2026
52-week range $159.24 to $382.54
Market cap
$10.2B
Revenue (last 12 months)
$440.5M
+22.6% year on year
Net margin
54.8%
P/E
50.6
on FY2025 diluted EPS

What Krystal Biotech, Inc. does

Krystal Biotech, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KRYS.

Revenue and profit by year

Revenue
FY21: $0 $0 FY21FY21: $0 $0 FY21FY23: $50.7M $50.7M FY23FY24: $290.5M $290.5M FY24FY25: $389.1M $389.1M FY25
Net income
FY19: -$10.9M -$10.9M FY19FY19: -$19.1M -$19.1M FY19FY20: -$32.2M -$32.2M FY20FY21: -$69.6M -$69.6M FY21FY21: -$140M -$140M FY21FY23: $10.9M $10.9M FY23FY24: $89.2M $89.2M FY24FY25: $204.8M $204.8M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$389.1M$161.3M$204.8M$6.84$188.9M
2024$290.5M$65.7M$89.2M$3.00$119.2M
2023$50.7M-$109.6M$10.9M$0.39-$100.6M
2021$0-$145.2M-$140M-$5.49-$153.5M
2021$0-$68.3M-$69.6M-$3.13-$116.3M
2020n/a-$33M-$32.2M-$1.71-$40.9M
Next report expected around November 2, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 3, 2025. Not a date the company has announced. See the report calendar

Where KRYS ranks in Health care

Revenue$389.1M
#205 of 523 in Health care · Top 39%
Revenue growth+33.9%
#110 of 437 in Health care · Top 25%
Net margin52.6%
#10 of 447 in Health care · Top 2%
Free cash flow margin48.5%
#5 of 408 in Health care · Top 1%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Krystal Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 3, 2026
    Quarterly results 8-K
  2. August 3, 2026
    Quarterly report 10-Q · period to June 30, 2026
  3. July 21, 2026
    Other event 8-K
  4. May 20, 2026
    Shareholder vote results 8-K
  5. May 4, 2026
    Passive stake changed SCHEDULE 13G/A
  6. May 4, 2026
    Exhibits 8-K
  7. May 4, 2026
    Quarterly report 10-Q · period to March 31, 2026
  8. April 29, 2026
    Passive stake (5% or more) SCHEDULE 13G
  9. April 3, 2026
    Annual report to shareholders ARS
  10. April 3, 2026
    Additional proxy material DEFA14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 16, 2026. Insider transactions on SEC

What is KRYS worth? A DCF from its reported cash flow

Insider trades

What the people running Krystal Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $18M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)
$0
last 90 days
Sold
$18M
last 90 days
Net sold
50,000
$18M
DateInsiderWhatSharesPriceValueFiling
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 520 $354.54 $184.4K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 2,029 $355.57 $721.5K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 3,297 $356.37 $1.2M Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 3,981 $357.57 $1.4M Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 3,143 $358.42 $1.1M Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 3,357 $359.39 $1.2M Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 2,266 $360.46 $816.8K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 1,214 $361.61 $439K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 2,010 $362.65 $728.9K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 573 $363.34 $208.2K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 1,358 $364.48 $495K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 847 $365.42 $309.5K Form 4
September 4, 2026 Krishnan Krish SPresident and CEO, Director, 10% owner Soldpre-planned (10b5-1) 405 $366.56 $148.5K Form 4
September 4, 2026 Krishnan SumaPresident, R&D, Director, 10% owner Soldpre-planned (10b5-1) 520 $354.54 $184.4K Form 4
September 4, 2026 Krishnan SumaPresident, R&D, Director, 10% owner Soldpre-planned (10b5-1) 2,006 $355.57 $713.3K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about KRYS

What does Krystal Biotech, Inc. do?

Krystal Biotech, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KRYS.

Is Krystal Biotech, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $241.5M on revenue of $440.5M, a net margin of 54.8%.

How much revenue does Krystal Biotech, Inc. make?

Over the twelve months to June 30, 2026 Krystal Biotech, Inc. reported revenue of $440.5M. That is 22.6% more than a year earlier.

When did Krystal Biotech, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 16, 2026.

Similar companies

AMGN
Amgen Inc
GILD
Gilead Sciences, Inc.
BIIB
Biogen Inc.
BNTX
BioNTech SE
NBIX
Neurocrine Biosciences Inc
EXEL
Exelixis, Inc.

Compare KRYS with

Compare KRYS with any company

Follow KRYS

Get an email when Krystal Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow KRYS: get an email when it files

Where the numbers come from

Financial figures are the values Krystal Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.